Antibodies to interleukin-like epithelial-mesenchymal transition inducer (ILEI)

US7745585B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Andreas Zophel · Neulengbach, AT
• Horst Ahorn · Weigelsdorf, AT
• Birgit Jung · Laupheim, DE
• Renate Konopitzky · Bad Vöslau, AT
• Karl-Heinz Heider · Stockerau, AT
• Norbert Kraut · Seattle, US
• Peter Seither · Biberach an der Riß, DE
• Thomas Waerner · Wien, AT
• Hartmut Beug · Wien, AT
• Martin Jechlinger · Wien, AT
• Ido M. Tamir · Wien, AT
• Andreas Weith · Eberhardzell, DE
• Stefan Gruenert · Wien, AT

Key dates

• Filing date: Sep 2, 2004
• Grant date: Jun 29, 2010
• Expiry date: Sep 24, 2025

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The functional characterization of ILEI to be a novel cytokine involved in epithelial/mesenchymal transition and the identification of biologically active ILEI provides the basis for generating ILEI inhibitors, in particular anti-ILEI antibodies, that are useful in the therapy of cancer, fibrosis and COPD.